Wednesday - April 12, 2017

New animation reveals lasers, flying cars and a cure for hunger are top priorities for children with scientific ambitions

It might sound like an unusual to-do list for a scientist, but lasers, flying cars and a cure for hunger were among the top priorities of students who lent their imaginations and vocal talents to an animation created to launch a free science laboratory for primary and secondary schools across the UK.

Reading, April 12 2017: But while talk of flying cookies and mixing fox and human DNA kept students occupied, it also provided valuable insight into children’s perceptions of a scientist, with many never having experienced science outside of their classroom walls.

Baylab – launched by Life Sciences company Bayer PLc – is a state-of-the-art science laboratory designed to act as a free resource to awaken the joy of discovery in school children and give them room to grow while supporting their classroom education. Baylab will provide hands-on science lessons to over 4,000 students aged 5-18 every year.


The opening of Baylab coincides with a study by Bayer which shows that seven out of ten STEM (Science, Technology, Engineering and Maths) teachers feel there is a lack of options for extracurricular activities and fields trips.


The study surveyed 500 teachers about their experience of science in schools, including their opinion on the importance of practical application and facilities.

Just one third of teachers feel their students fully understand how their subjects relate to real life. A lack of facilities and equipment was cited as the main reason for this, followed by time constraints.


Baylab’s manager, Emma Schierbaum, a science teacher and bio-chemist said: “Practical experiments can often suffer due to lack of facilities and equipment, making it difficult to run an engaging lesson that relates to real life settings.


“We are giving students of all levels and abilities the chance to extract their own DNA, to characterise the proteins of an enzyme and even work through crime scene forensics. The experiments have been designed to give students an insight into how science is used in everyday life.”


Part of an £11m investment in its new Regional UK/Ireland HQ, Baylab aims to inspire young people to pursue opportunities in Life Sciences and strengthen the UK STEM talent pool from the bottom-up; its experiments have been developed to support teachers with delivering the national curriculum and fill the hands-on science gap that many teachers experience due to time and cost constraints.


Dr. Alexander Moscho, CEO of Bayer UK and Ireland said: “At Bayer we are well aware that sound scientific expertise is essential for meeting the challenges of the future. That’s why the company is increasingly gearing its strategy towards the promotion and strengthening of science education as well as our own research activities. Baylab will help students discover the magic of science and how they can apply their knowledge to real world scenarios. It will work alongside our other initiatives including our award-winning apprenticeship programme and graduate scheme to encourage more young people to pursue a career in life science.”


To watch the animation, visit:


For more information and to register a school with Baylab, headteachers, science coordinators, teachers and parents of children aged 5-18 should visit 





Lucy Pritchard

Tel : 07393 753433

E-Mail :


Notes to Editors



The UK Baylab is the 14th school’s laboratory to be opened worldwide by Bayer, the first having been opened in Wuppertal, Germany in 1998. Today there are Baylabs in 5 out of 7 continents, each one inspiring young minds to be passionate about science and the endless possibilities it poses.


Baylab sits in the heart of Bayer’s home among Thames Valley businesses that together contribute the second highest level of GDP to UK economy.  


Bayer wants to ensure that Baylab is not just for students in the South East, but gives schools across the country an opportunity to visit a center of scientific excellence which can enhance and compliment the National Curriculum nationwide.


Bayer Plc

Bayer is a global innovation focused life science company specializing in animal and human healthcare and crop science, with a focus on addressing the unmet challenges of the future.

Bayer has a strong heritage in the UK beginning in 1875 and currently employs around 1,000 people, with around £1bn sales and a UK R&D investment of around £50m annually.


As the second fastest growing pharma company in 2016 and eighth largest pharma company in the UK, and a major investor in UK life sciences, we care passionately about developing healthcare solutions that benefit UK patients and the NHS.


Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to


Bayer’s offices in the UK and Ireland are located in Reading (head office), Cambridge and Dublin. For more information, go to

Follow us on Twitter at:

Follow us on YouTube at:



Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.